171 related articles for article (PubMed ID: 21777013)
41. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
42. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG; Germino FW; Neutel JM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
[TBL] [Abstract][Full Text] [Related]
43. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
Weir MR; Hsueh WA; Nesbitt SD; Littlejohn TJ; Graff A; Shojaee A; Waverczak WF; Qian C; Jones CJ; Neutel JM
J Clin Hypertens (Greenwich); 2011 Jun; 13(6):404-12. PubMed ID: 21649839
[TBL] [Abstract][Full Text] [Related]
44. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
Roth EM; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
J Clin Hypertens (Greenwich); 2013 Aug; 15(8):584-92. PubMed ID: 23889722
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy.
Weir MR; Shojaee A; Maa JF
Postgrad Med; 2013 Mar; 125(2):124-34. PubMed ID: 23816778
[TBL] [Abstract][Full Text] [Related]
46. Olmesartan medoxomil: a review of its use in the management of hypertension.
Scott LJ; McCormack PL
Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
[TBL] [Abstract][Full Text] [Related]
47. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.
Oparil S; Chrysant SG; Kereiakes D; Xu J; Chavanu KJ; Waverczak W; Dubiel R
J Clin Hypertens (Greenwich); 2008 Dec; 10(12):911-21. PubMed ID: 19120717
[TBL] [Abstract][Full Text] [Related]
48. Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Ram CV; Sachson R; Littlejohn T; Qian C; Shojaee A; Stoakes KA; Neutel JM
Am J Cardiol; 2011 May; 107(9):1346-52. PubMed ID: 21497211
[TBL] [Abstract][Full Text] [Related]
49. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
50. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.
Kereiakes DJ; Neutel J; Stoakes KA; Waverczak WF; Xu J; Shojaee A; Dubiel R
J Clin Hypertens (Greenwich); 2009 Aug; 11(8):411-21. PubMed ID: 19695028
[TBL] [Abstract][Full Text] [Related]
51. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
Ram CV
Curr Med Res Opin; 2009 Jan; 25(1):177-85. PubMed ID: 19210150
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.
Weir MR; Punzi HA; Flack JM; Stoakes KA; Chavanu KJ; Li W; Dubiel R
Postgrad Med; 2011 Jan; 123(1):80-7. PubMed ID: 21293087
[TBL] [Abstract][Full Text] [Related]
53. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Rosenbaum D; Girerd X
Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
[TBL] [Abstract][Full Text] [Related]
54. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Omboni S; Malacco E; Mallion JM; Volpe M
Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
[TBL] [Abstract][Full Text] [Related]
55. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
Rump LC; Sellin L
Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758
[TBL] [Abstract][Full Text] [Related]
57. Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.
Ruilope LM
Vasc Health Risk Manag; 2008; 4(6):1237-48. PubMed ID: 19337537
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Punzi HA
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):229-39. PubMed ID: 19296759
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.
Chrysant SG; Oparil S; Melino M; Karki S; Lee J; Heyrman R
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):475-82. PubMed ID: 19751459
[TBL] [Abstract][Full Text] [Related]
60. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
